KYMR NASDAQ
Kymera Therapeutics, Inc.
1W: +6.3%
1M: +2.6%
3M: +8.2%
YTD: +57.8%
1Y: +98.8%
3Y: +865.9%
5Y: +112.9%
$117.57
+2.73 (+2.38%)
After Hours: $116.92 (-0.64, -0.55%)
Weekly Expected Move ±5.5%
$99
$105
$111
$117
$123
Credit Risk of going bust: lower than 78% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.12 (down 99.9%), Kymera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $82.2M against a stock market value of $9.45B.
Distance to default 9.26 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $41.1M (short-term plus half of long-term), stock volatility 57.7%; Altman Z'' 10.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.12 (down 99.9%), Kymera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $82.2M against a stock market value of $9.45B.
Distance to default 9.26 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $41.1M (short-term plus half of long-term), stock volatility 57.7%; Altman Z'' 10.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
1 bullish
0 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Oppenheimer's top 50 small- and mid-cap Buy list
Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
Cathie Wood’s Ark weekly recap: cuts SpaceX exposure alongside HOOD, TER, boosts CRWV, VCYT
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 5% – What’s Next?
Bank of America Corp DE Takes Position in Kymera Therapeutics, Inc. $KYMR
California State Teachers Retirement System Raises Stock Position in Kymera Therapeutics, Inc. $KYMR
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Atlas Venture Life Science Advisors LLC Decreases Stock Holdings in Kymera Therapeutics, Inc. $KYMR
Can KT-621 Mark a Turning Point for Kymera Therapeutics?
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp
215,588 Shares in Kymera Therapeutics, Inc. $KYMR Acquired by Bank of New York Mellon Corp
5,538,210 Shares in Kymera Therapeutics, Inc. $KYMR Purchased by BlackRock Inc.
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up – Here’s Why
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Kymera's CEO Sold $6 Million in Stock After a 170% Run
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
Why Kymera Therapeutics Stock Popped This Week
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
Kymera Therapeutics stock surges on early trial enrollment By Investing.com - Investing.com Nigeria
Kymera stock climbs on expedited eczema study (KYMR:NASDAQ) - Seeking Alpha
Kymera Therapeutics (KYMR) Accelerates Timeline for Atopic Derma - GuruFocus
Kymera Therapeutics (NASDAQ: KYMR) accelerates KT-621 Phase 2b AD data - Stock Titan
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
symbol__ Stock Quote Price and Forecast - CNN
KYMR (KYMR) Rule 144: Atlas Venture and Bruce Booth report multi‑date sales - Stock Titan
KYMR (NASDAQ: KYMR) Atlas Venture and Booth disclose multiple stock disposals - Stock Titan
Kymera Therapeutics (NASDAQ: KYMR) wins support on directors, pay and 2026 auditor - Stock Titan
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
Kymera taps Felix Baker as board chairman; Booth stays on - Stock Titan
KYMR affiliates report large June share sales (NASDAQ: KYMR) - Stock Titan
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Kymera Therapeutics Stock (KYMR) Opinions on Director's Substantial Share Sale - Quiver Quantitative
Why Kymera Therapeutics (KYMR) Is Up 5.7% After Positive Cross-Population KT-621 Phase 1 Data - simplywall.st
Kymera Therapeutics(KYMR.US) Director Sells US$48.59 Million in Common Stock - Moomoo
Atlas funds tied to Kymera (KYMR) sell 478,198 shares in June - Stock Titan
Insider Sale: Director at $KYMR Sells 9,584 Shares - Moomoo
Kymera (NASDAQ: KYMR) CBO exercises options and sells 2,500 shares at $99 - Stock Titan
$KYMR stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
Kymera Therapeutics (KYMR) Stock Could Be 24% Undervalued After KT 621 And KT 579 Data - simplywall.st
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs
Brookline Capital Markets Increases Price Target for Kymera Therapeutics (KYMR)
Assessing Kymera Therapeutics (KYMR) Valuation After Recent Share Price Rebound
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study - Yahoo Finance
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
How The Kymera Therapeutics (KYMR) Investment Narrative Is Evolving Without New Analyst Targets
Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?
Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data
Kymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical Progress
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera expects KT-579 Phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics GAAP EPS of -$0.71 beats by $0.20, revenue of $34.36M beats by $26.13M
Earnings Scheduled For April 30, 2026
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics Q1 2026 Earnings Preview
Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside
Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue Estimates
Kymera Therapeutics (NASDAQ:KYMR) COO Sells $27,000.00 in Stock
B. Metzler seel. Sohn & Co. AG Purchases New Holdings in Kymera Therapeutics, Inc. $KYMR
FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic Asthma
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $374,185.23 in Stock
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $472,590.00 in Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Analysts
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $174,700.00 in Stock
Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $723,100.00 in Stock
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline
SG Americas Securities LLC Grows Position in Kymera Therapeutics, Inc. $KYMR
Elena Ridloff Sells 4,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 14,640 Shares
Kymera Therapeutics (NASDAQ:KYMR) Director Elena Ridloff Sells 7,400 Shares of Stock
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 7,600 Shares of Stock
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Jeremy Chadwick Sells 24,727 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Jeremy Chadwick Sells 91,250 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of “Moderate Buy” from Analysts